Allucent
Buying intent
28 tracked signals | Top 15 topics are below | Sales and Operations are carrying most of it.
Attention by team
LinkedIn activity, by teamWhere Allucent's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.
Topics being researched
30-day windowEvery tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.
today
today
2d ago
26d ago
14d ago
16d ago
today
9d ago
11d ago
12d ago
12d ago
16d ago
25d ago
10d ago
16d ago
Need intent for a specific topic or industry?
We track the full taxonomy across every account in the graph — including themes not shown on this page.
Who's active at Allucent
verified title on fileTitles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.
Primary products / business lines
LinkedIn company profileAllucent is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. The company is purpose-built through the convergence of leading providers to address this unmet need. Today, Allucent is a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics and clinical pharmacolo
Top accounts researching Allucent
names withheld on the public pageThese are companies whose own people brought up Allucent unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.
3,463 companies · 13,523 people are researching Clinical Trials
Allucent's own team shows 4 signals on this topic. No one outside Allucent has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.
- Artificial Intelligence129,094 cos · 649,540 people
- Pharmaceutical5,568 cos · 20,395 people
Buyer profile
company size · seniorityCompany size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.
Buying committee functions
Employee job titles (LinkedIn)Operations — 2 people; Sales — 2 people; HR / Talent — 1 person
What's been said
public posts by Allucent's teamNo public post naming Allucent has surfaced in the past year, so this is what Allucent's own team is posting about publicly — their topics, in their words.
AI just crossed into system-level impact—and most people are still treating it like a tool. This week made that clear: From a project / operations perspective, this changes how we think about risk, workflows, and decision-making. • OpenAI launched a restricted cybersecurity model • Anthropic models are raising global regulatory concerns • Financial institutions are actively preparing for AI-driven cyber risks • Meta is scaling AI adoption at massive consumer levels • AI is driving record investment and dealmaking activity Here’s the shift: 👉 AI is no longer just productivity software It is now: • a security variable • a financial system factor • a platform power play The real takeaway: The AI race is no longer just about capability. It’s about: ✔ Control ✔ Risk management ✔ Distribution at scale Curious how others are thinking about this— Are you already seeing AI impact risk or operations in your work?
Apr 2026